Trial Profile
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jun 2015 ClinicalTrials.gov record.
- 23 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.